{
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "document": "Zimmerman_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 1
  },
  "completeness_stats": {
    "existing_evidence": 4,
    "new_evidence_found": 1,
    "total_evidence": 5
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "RIV4 was Flublok",
      "relevance_explanation": "This quote directly identifies Flublok as the recombinant influenza vaccine (RIV4) under study, which is necessary context for understanding subsequent statements about its production platform."
    },
    {
      "id": 2,
      "quote": "Relative effectiveness of various vaccine formulations provide important input for vaccine policy decisions. We used electronic databases to conduct a test negative case control study to determine relative vaccine effectiveness (rVE) of recombinant influenza vaccine (RIV4) compared with standard dose vaccines (SD-IIV4) against influenza hospitalization.",
      "relevance_explanation": "This quote establishes that the study is focused on recombinant influenza vaccine (RIV4), which is Flublok, and sets the context for discussing its characteristics, including its production method."
    },
    {
      "id": 3,
      "quote": "Two large studies have explored rVE of recombinant quadrivalent influenza vaccine (RIV4). The Medicare beneficiaries study [10] using retrospective data as described above, reported significant rVE of RIV4 vs. SD-IIV4) against influenza related hospital encounters. Secondly, a randomized controlled trial (RCT) found significant rVE of RIV4 compared with SD-IIV4 among adults 50 years old, but not for adults 65 years old [11].",
      "relevance_explanation": "This quote further clarifies that RIV4 is a recombinant vaccine, which is a key aspect of the claim regarding its novel production platform."
    },
    {
      "id": 4,
      "quote": "c RIV4: Flublok.",
      "relevance_explanation": "This quote explicitly equates RIV4 with Flublok, confirming that all references to RIV4 in the document pertain to Flublok and its production method."
    },
    {
      "id": "comp_1",
      "quote": "tion, egg free vaccines manu fac bin ant technologies have accine; PA-SIIS, Pennsylvania Statewide Randomized controlled trial; RIV4",
      "relevance_explanation": "This quote references 'egg free vaccines' and 'recombinant technologies' in the context of RIV4, which is Flublok, supporting the claim that Flublok is produced using a novel, non-egg-based recombinant technology platform.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}